SHMT1 Polymorphism in Parkinson's Disease,

Assiut University80 enrolled

Overview

Parkinson Disease (PD) is the most common movement disorder and represents the second most common degenerative disease of the central nervous system . SHMT has been shown to be associated with various diseases.

This case -control observational prospective study will conducted on 40 patients with PD.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Study the Role of SHMT1 Polymorphism in Parkinson Disease

Interventions

SHMT1 polymorphismGENETIC

It is to identify the role of SHMT1polymorphism in PD and examine the relationship between it and Severity of PD.

Eligibility

Sex: ALLMin age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Patients age ≥ 50 years. * Patients with PD diagnosed according to the United Kingdom Parkinson's Disease Society Brain Bank (UK PDS Brain Bank diagnostic criteria) Exclusion Criteria: * Patients with parkinsonian plus syndrome * Patients with secondary parkinsonism * Patients with other chronic comorbidities (renal, hepatic, and endocrinal disturbances and chronic chest disease.) * Past and /or present history of epilepsy. * Patients with disturbed conscious level.

Locations (1)

Effat abdelhady tony

Asyut, Egypt

RECRUITING

Outcomes

Primary Outcomes

polymorphism of SHMT1gene

Time frame: one year

Secondary Outcomes

the role of SHMT1plymorphism in pathogenesis PD

Time frame: one year

Study the relationship of Shmt1 polymorphism to the severity of Parkinson disease

Time frame: One year

Central Contacts

Effat a Tony, MD

CONTACT

+201097330309 effattony@aun.edu.eg

abeer a tony, MD

CONTACT

+201005389084 abeer.tony@aswu.edu.eg

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.